Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 18

Trial readouts

GLP-1 telehealth prescribing for addiction

Telehealth firms are offering off-label GLP-1 drugs for addiction. Two semaglutide trials show a signal, but not approval or class-wide proof.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide and Retinopathy in Type 1

A chart review found similar proportions of new diabetic retinopathy with off-label tirzepatide and matched controls in type 1 diabetes.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide vs Semaglutide in Arthroplasty

A records study found similar early outcomes after knee or hip arthroplasty, with two uncertain differences appearing at two years.

23 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Nanomedicine Weight Loss in Mice

A dextran nanomedicine reduced weight and body fat in mice without lower food intake. No human weight-loss evidence exists.

22 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Incretins and Doxorubicin Heart Injury

A 2026 review found heart-protective signals for GLP-1 drugs and tirzepatide in rodents, with no eligible human studies.

22 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Tirzepatide After Lumbar Fusion

A retrospective cohort links tirzepatide with fewer mechanical complications after lumbar fusion, but it cannot establish cause and effect.

22 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Oral vs injectable incretins

What trial evidence can and cannot say when comparing oral orforglipron with injectable semaglutide and tirzepatide.

22 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Reading a reply about the HISTORI trial

A new letter responds to a comment on the HISTORI semaglutide analysis. Its indexed record confirms correspondence, not the content of either letter.

22 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Reading the Semaglutide Aspiration Reply

The semaglutide reply confirms scientific correspondence, but its indexed record contains no argument, rebuttal, or new patient data.

22 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Can semaglutide reduce crime?

A planned 1,200-person US trial will test semaglutide for addiction recovery and track arrests, incarceration, housing and work.

22 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

ESSENCE Japanese Subgroup Readout

The Japanese ESSENCE subgroup broadly matched the main semaglutide MASH result, but its fibrosis estimate remained imprecise.

22 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semax and Selank blends: evidence gaps

No published human trial establishes that a Semax and Selank blend is effective or safe, or that it matches the compounds studied separately.

22 Oct 2026 · PeptideMethods Editorial Team · 4 min read